Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
Abramson Cancer Center at Penn Medicine
Study ID
NCT06332131
Status
Enrolling By Invitation

Conditions

  • Breast Cancer
  • Cardiotoxicity
  • Coronary Microvascular Dysfunction
  • Lung Cancer (NSCLC)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

This is an observational study that includes patients with breast cancer or non-small cell lung cancer who will be treated with immune checkpoint inhibitor (ICI) therapy. The investigators will use echocardiograms, blood draws, and PET stress tests to understand how ICI therapy affects the heart and circulatory system.

Key Dates

Start date
Jan 15, 2025
Status verified
Feb 2026
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
25 participants (estimated)

Primary Outcome Measure

Incidence of new abnormal myocardial blood flow reserve (MBFR) [ Time Frame: 3 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Abramson Cancer Center at University of PennsylvaniaPhiladelphiaPennsylvania19104-

Find similar trials in Philadelphia, PA

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
Abramson Cancer Center at University of Pennsylvania· Philadelphia, PA

Related Studies